January 31, 2019 / 11:02 PM / 6 months ago

Allergan's Forest must face off-label marketing lawsuit - 1st Circuit

A federal appeals court has revived a lawsuit accusing Allergan PLC’s Forest Laboratories of misleading the public about the effectiveness of its antidepressants Celexa and Lexapro in treating children, but said the case could not proceed as a class action.

The 1st U.S. Circuit Court of Appeals in Boston on Wednesday ruled that a lower-court judge erred in dismissing racketeering and state-law claims against Forest brought by a union health insurance fund and a parent whose child used both drugs.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2DLLBTk

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below